Neurofibromatosis Type 2: A Pandora’s Box of Variable Presentations

Abstract

Introduction Neurofibromatosis type 2 (NF2) also known as MISME syndrome stands for multiple inherited schwannomas, meningiomas, and ependymomas in the peripheral and central nervous system. It is a rare disorder of autosomal dominant inheritance due to mutations of a tumor-suppressor gene on the chromosome 22q12. Clinically, it is characterized by multiple benign tumors arising in both the central and peripheral nervous system, particularly from the bilateral vestibular nerve, in more than 90% of the patients, with more than two thirds of them developing spinal tumors.

Materials and Methods Here, we studied the variable presentations of cases of NF2, and thorough evaluation of patients was done by contrast MRI of brain and spine. Also, evaluation of ocular manifestations and cutaneous features was done in cases of NF2, and a follow-up was done for a period of 18 months with monitoring of cranial and spinal lesions.

Conclusion We studied the various presentations of NF2 and found that a significant proportion of the patients presented with nonvestibular tumors as the initial presentation, with bilateral cerebellopontine angle lesions being an incidental finding; also, the age of presentation in half of the patients was less than 30 years, and so we can conclude that in young patients with spinal tumors or multiple meningiomas, a thorough evaluation regarding family history and various features of NF2 should be done, so that early identification of the disease could be done and patients can be benefitted from timely interventions.

Keywords

neurofibromatosis type 2 - MISME syndrome - schwannoma

Publication History

Article published online:
29 April 2021

• References

• 1 Evans DGR, Huson SM, Donnai D. et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992; 84 (304) 603-618
• 2 Mautner VF, Lindenau M, Baser ME. et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996; 38 (05) 880-885
• 3 Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence and clinical evidence for heterogeneity. Am J Med Genet 1994; 52 (04) 450-461
• 4 Patronas NJ, Courcoutsakis N, Bromley CM, Katzman GL, MacCollin M, Parry DM. Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology 2001; 218 (02) 434-442
• 5 Mautner VF, Tatagiba M, Lindenau M. et al. Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. Am J Roentgenol 1995; 165 (04) 951-955
• 6 Dow G, Biggs N, Evans G, Gillespie J, Ramsden R, King A. Spinal tumors in neurofibromatosis type 2. Is emerging knowledge of genotype predictive of natural history?. J Neurosurg Spine 2005; 2 (05) 574-579
• 7 Lee M, Rezai AR, Freed D, Epstein FJ. Intramedullary spinal cord tumors in neurofibromatosis. Neurosurgery 1996; 38 (01) 32-37
• 8 Egelhoff JC, Bates DJ, Ross JS, Rothner AD, Cohen BH. Spinal MR findings in neurofibromatosis types 1 and 2. Am J Neuroradiol 1992; 13 (04) 1071-1077
• 9 Rennie AT, Side L, Kerr RS, Anslow P, Pretorius P. Intramedullary tumours in patients with neurofibromatosis type 2: MRI features associated with a favourable prognosis. Clin Radiol 2008; 63 (02) 193-200
• 10 Aboukais R, Baroncini M, Zairi F. et al. Prognostic value and management of spinal tumors in neurofibromatosis type 2 patients. Acta Neurochir (Wien) 2013; 155 (05) 771-777
• 11 Baser ME, Friedman JM, Aeschliman D. et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002; 71 (04) 715-723
• 12 Miyazawa N, Hida K, Iwasaki Y, Koyanagi I, Abe H. MRI at 1.5 T of intramedullary ependymoma and classification of pattern of contrast enhancement. Neuroradiology 2000; 42 (11) 828-832
• 13 Sun B, Wang C, Wang J, Liu A. MRI features of intramedullary spinal cord ependymomas. J Neuroimaging 2003; 13 (04) 346-351